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 Background: Infections cause significant morbidity and mortality in children with cancer, 
which may be related to the cancer or treatment received. There is paucity of data on the 
epidemiology of bloodstream infection (BSI) in sub-Saharan Africa. To address this 
knowledge gap, the present study was conducted at Red Cross War Memorial Children`s 
Hospital (RCWMCH) in Cape Town, South Africa. 
Methods: 
Structured literature review: From 1 April 2016 to 31 May 2016 a PubMed search was 
undertaken on BSI in Paediatric Oncology. The search string used was (bacteraemia OR 
blood stream infection) AND (paediatric OR pediatric) AND (oncology). Studies that did not 
describe infection patterns, risk factors for infection, morbidity/mortality, articles not in 
English and those exclusively describing neonatal or ICU patients were excluded from full 
review. 
Retrospective cohort study: A retrospective cohort study was conducted at the 
haematology-oncology unit of RCWMCH. All positive blood cultures from RCWMCH 
oncology patients taken between 1 January 2012 and 31 December 2014 were retrieved to 
identify patients who had BSI. 
Results: 
Structured literature review: 508 abstracts / articles were initially retrieved and screened. 
478 studies were excluded as per the literature review exclusion criteria. Thus, 30 articles 
were included in full analysis, 17 retrospective studies, 4 prospective multicentre studies, 6 
prospective single centre studies, 2 systematic reviews and 1 case report. All were 
observational studies. This literature review showed that BSI is a frequent and important 
cause of morbidity and mortality in paediatric oncology. Gram-positive bacteria was noted to 
be the leading type of pathogen causing BSI. Increased risk of BSI may be from the cancer 
itself, chemotherapy, hospitalisation, central venous catheter insertion, and oncology patients 
were at risk of multi-drug resistant infection.  Research gaps noted included paucity of 
studies from Sub-Saharan Africa, limited analysis of the antimicrobial susceptibility of 
causative microorganisms and limited description of fungal BSI in oncology patients. 
Retrospective cohort study: From 436 positive blood culture results, 150 BSI episodes were 
identified amongst 89 patients; 49.1% of the culture isolates were Gram-positive bacteria, 
41.6 were Gram-negative bacteria and 9.3% were fungal. Coagulase Negative 
Staphylococcus and Viridans Group Streptococcus were the most common Gram-positive 
isolates, and Escherichia coli and Klebsiella species the commonest Gram-negative isolates. 
The majority of BSI episodes occurred in patients with haematological malignancies (74%), 
in the presence of severe neutropaenia (76.4%) and whilst on or following chemotherapy 
(88%). Complications occurred in 14% of the BSI episodes. Fungal infections had the highest 
prevalence of complications (21.4%). Three children died during BSI as a result of multidrug 
resistant isolates, giving a case-fatality rate of 2%.  
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Conclusion: The findings of our cohort study show that BSI are mainly caused by Gram-
positive bacteria and associated with a low case-fatality rate. The results of this study are 
consistent with worldwide experience of BSI in paediatric oncology patients. This study 
provides an understanding of the spectrum of organisms causing BSI and the outcome of BSI 
in a sub-Saharan African context.  
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Chapter 1: Introduction and literature review 
1.1 Introduction 
  Infections are a major contributing factor to morbidity and mortality in children with 
cancer.1-3 This may be due to risk factors from the cancer itself or factors related to treatment. 
These main groups of factors may increase risk of infection by decreasing the effectiveness of 
innate immunity, decreasing the functional capacity of the acquired immune system and 
increased exposure to pathogens.4 
 The innate system may be weakened by decreased integrity of epithelial barriers, decreased 
ability to clear secretions or decreased function of leukocytes.1 Chemotherapy, radiotherapy, 
prophylactic antibiotics, surgery, hematopoietic stem cell transplant (HSCT) and the cancer 
itself may all contribute to this.1,2,5,6 Neutropaenia in cancer patients is associated with 
increased risk of infections and poor outcomes of the infections. These risks are more 
pronounced with prolonged neutropaenia and severe neutropaenia.7 Severe and prolonged 
neutropaenia is also associated with poor infectious episode outcomes.8 In cancer patients the 
adaptive immune system may be suppressed due to decreased levels B lymphocytes and T 
lymphocytes that would normally produce an immunological memory based antigen 
detection response, resulting in reduced humoral and cell mediated immunity. Reduced 
functional capacity of the adaptive immune system leads to reduced capacity to produce 
antibodies, reduced activation of the complement system and reduced activation of natural 
killer lymphocytes and macrophages. Bone marrow suppression or infiltration by the cancer 
itself may cause these immune alterations. Chemotherapy, radiotherapy and HSCT may also 
cause dysfunction of the adaptive immune response.9,10 
   Haematological cancers have been shown to confer a greater infection risk than solid 
tumours.11 This is more prominent in patients who are neutropaenic as a result of bone 
marrow infiltration, craniospinal radiotherapy or increasingly intensive chemotherapy 
regimens.12,13  
 Cancer patients usually have prolonged hospital stay, indwelling vascular catheters for 
chemotherapy, multiple hospital procedures and neutropaenia which put them at risk of both 
community- and hospital-acquired infection.4,6,8,12,14-18   Hospital-acquired infection (HAI) is 
associated with higher morbidity and mortality, and frequently caused by multidrug resistant 
pathogens.4,11,12  
 These same factors that increase their risk for developing infections may also increase the 
risk of complicated infections. Cancer patients may have different infection patterns caused 
by different pathogens in comparison to the general paediatric population. For instance, 
patients with mucositis have an increased risk of developing Viridans group streptococcal 
(VGS) infections particularly in acute myeloid leukaemia (AML).19-21  Coagulase negative 
Staphylococci (CONS) and Bacillus cereus have also been shown to occur with increased 
frequency in oncology patients.8,21  In the general paediatric population these oral isolates are 
not a common cause of systemic infection.22 The presence of specific types of central venous 
catheters (CVCs) may also contribute to different infection patterns.22,24 The risk of catheter-
related infection itself varies with the type of CVC.11,15CVC related infections may also 
increase the risk of poor outcome since nosocomial infections that may develop from 
colonised CVC are frequently caused by multi-drug resistant pathogens.16 Whereas oral 
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prophylactic antibiotics reduce infection incidence they may also alter the pattern of infection 
due to alteration of gastroenterological tract colonisation.25 
1.2 Purpose of Literature review: 
1- To describe the spectrum of bacteria and fungi causing bloodstream infections (BSI)
amongst paediatric oncology patients.
2- To evaluate the extent of morbidity and mortality caused by BSI in paediatric oncology
patients.
3- To assess risk factors for BSI in paediatric oncology patients.
4- To evaluate the antibiotic susceptibility patterns of blood culture isolates in paediatric
oncology patients.
5- To identify gaps in the knowledge of BSI in paediatric oncology patients within an African
setting.
1.3 Search strategy. 
 An internet search strategy was undertaken on PubMed. The search string used was 
(bacteraemia OR blood stream infection) AND (paediatric OR pediatric) AND (oncology). 
This search came out with 508 articles. This literature search was completed between 1 April 
2016 and 31 May 2016. 
Abstracts were reviewed for inclusion for full literature review. 
Criteria for inclusion included 
1- Articles in English
2- Studies needed to be done in a paediatric cancer population. A population was
considered to be paediatric if the patients were of the aged 18 years or less. If the
population was mixed, a separate description of the paediatric population was needed.
3- Studies needed to have described at least one of the following; infection patterns, risk
factors for infection, antibiotic susceptibility patterns, morbidity or mortality patterns.
Studies done exclusively in a neonatal or paediatric intensive care unit were excluded to 
reduce bias as they may have a different infection pattern. 
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(blood stream infection OR bacteremia) AND 
(paediatric OR pediatric) AND (oncology) 
508 abstracts retrieved and screened 
Excluded if not describing at least one of the following;  infection 
pattern, risk factors for infection, morbidity/mortality pattern, 
antibiotic susceptibility patterns (326 excluded)  
182 articles were retrieved 
Excluded if not in English, article not describing paediatric cancer 
patients, article exclusively describing neonatal and ICU patients (152 
excluded) 
30 articles included in full analysis 
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Table 1: Summary of reviewed literature 
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-272 BSI 
-Risk factors reported for HAI were 
prolonged hospitalisation, 
haematological malignancy, 
neutropenia and malignancy relapse 
-Gram-negative bacteria aetiological 
factor for majority of HAI 
identified. 
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-HSCT and younger age increase 
risk for BSI. 
 
Abbreviations:  ALL, acute lymphoblastic leukaemia;  ALT, antimicrobial lock therapy;   AML, acute myeloid leukaemia;  BSI, bloodstream infection;  CABSI, 
catheter associated bloodstream infection;  CLABSI, central line associated bloodstream infection;  CONS, coagulase negative staphylococcus;   CRBSI, catheter 
related bloodstream infection;  CVC, central venous catheter;  ESKAPE pathogens, enterobacter spp, methicillin resistant staphylococcus aureus, klebsiella 
pneumonia, acinetobacter baumannii, pseudomonas aureginosa, enterococcus spectrum of pathogens;  HAI, hospital acquired infections;  HSCT,  haematopoietic 
stem cell transplant; NOPHO, Nordic society of paediatric haematology and oncology;  VAD, venous access device;  VGS, viridans group streptococcus. 
 
 
Quality of Evidence 
 Thirty articles were critically reviewed. Of these 17 were retrospective studies, 4 were 
prospective multicentre studies, 6 were prospective single centre case series studies, 2 were 
systematic reviews and 1 case report.  
  All these articles described observational studies. From these thirty studies, 20 reported on 
BSI in a whole paediatric oncology cohort, 6 focussed on CVC related or associated BSI and 
4 described BSI in haematological cancer cohorts. The majority of the studies were 
observational retrospective cohort studies, possibly due to the relative ease of conducting 
such studies. Although observational studies are low quality studies, these studies originated 
from a variety of geographical settings and populations.  
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There were consistencies in the findings in most of the articles as reported below including 
the pattern of common causes of BSI in paediatric oncology patients and the risk factors for 
BSI such as haematological cancers. These consistent findings across studies suggest that the 
literature is reliable. 
 
1.4 Interpretation of literature 
1- Pattern of pathogens causing BSI in paediatric oncology patients. 
2- Characteristics of cancer patients in relation to the BSI. 
3- BSI-associated morbidity and mortality. 
4- Variation of BSI pathogens in relation to cancer diagnosis. 
5- Factors influencing morbidity and mortality in cancer patients with BSI. 
6- BSI-associated risk factors. 
7- Antibiotic susceptibility patterns. 
 
 
1.4.1 Pattern of pathogens causing BSI in paediatric oncology patients 
  Most BSI in children with cancer has been shown to be caused by Gram-positive 
pathogens.8 This has been attributed to the intensive chemotherapeutic regimens, antibiotic 
prophylaxis that results in changes to the bacterial flora of the gastrointestinal tract, mucositis 
that may be related to chemotherapy or oral infections in neutropaenic patients, and 
indwelling CVCs.20,26 
  For the period 2008-2012, 56.6 % of all pathogens isolated from blood culture specimens at 
RCWMCH were Gram-negative bacteria. This analysis was not confined to oncology patients 
but included results from all children admitted to RCWMCH.27 In contrast, Gram-positive 
bacteria are the predominant group of pathogens that cause BSI in paediatric oncology 
patients.20 The most common Gram-positive bacteria being coagulase negative 
Staphylococcus (CONS) and VGS.11  
 A study in paediatric haematology-oncology patients completed in Johannesburg between 
1991 and 1995 showed that Gram-positive bacteria were the main cause of BSI accounting 
for 70% of positive blood cultures isolates. Whereas Gram-negative bacteria (20%) and fungi 
(10%) were responsible for the remaining positive blood cultures.15 This study only analysed 
patients with positive blood cultures and therefore did not describe the aetiology all invasive 
infection episodes. 
Risk factors have been described for Gram-negative BSI in paediatric oncology patients. 
Studies in Israel showed that Gram-negative infections are related to the presence of tunnel 
external CVC devices.23,24 Furthermore, a Mexican study showed predominance of Gram-
negative infections in HAI.4 
 Fungal aetiology of BSI was not documented in all articles reviewed. Although not a major 






1.4.2 Characteristics of cancer patients in relation to the BSI  
 Oncology patients are known to be at increased risk of developing infection when compared 
to patients with non-malignant conditions .4,12,20,28 Al-Mulla et al demonstrated that 
haematological malignancy patients have a higher risk of developing BSI than patients with 
other malignancies.11 In this study in Qatar 54% of BSI occurred in patients with leukaemia, 
47% in children with acute lymphoblastic leukaemia (ALL) and 7% in those with AML. The 
difference in the distribution of BSI between patients with leukaemia and those with 
lymphomas or solid tumours was statistically significant. This could be attributed to the 
primary oncological malignancy or aggressive chemotherapy such patients undergo. This 
difference in occurrence of BSI between types of malignancies may be reduced if aggressive 
chemotherapy regimens are also administered to patients with solid tumours as shown by 
Escande et al in France.26 When patients with solid tumours received aggressive 
chemotherapy the difference in the distribution of BSI in relation to the underlying diagnosis 
was not shown to be statistically significant. 
 Separate studies have also shown that patients with AML have increased risk of infection in 
comparison to other malignancies. Tsai et al reported that patients with AML in Taiwan 
experience the highest infection density (5.26 BSI 1000 patient days).29 Similarly, Castagnola 
et al in Italy demonstrated that patients with AML have a higher infection risk (IR) compared 
to those with ALL.19 In this study the overall IR, reported as the number of BSI episodes per 
100 days, was 0.106. Patients with AML and ALL had infection risks of 0.315 and 0.092 
respectively. The IR also differed in relation to the phase of chemotherapy, with a highest IR 
occurring in patients receiving second line intensive chemotherapy. This demonstrates that 
not only may the primary oncological diagnosis have an impact on the occurrence of a BSI, 
but also the intensity and phase of chemotherapy. Alexander et al and Yacobovich et al 
similarly reported patients with AML having a higher risk for BSI in comparison to those 
with other oncological diagnoses.2,13  
 
1.4.3 BSI-associated morbidity and mortality 
 Bloodstream infection contributes significantly to morbidity and mortality in paediatric 
oncology patients.1,6 This remains a challenge as newer and more aggressive oncological 
treatment modalities increase the risk of BSI. 
 The extent and severity of morbidity and mortality has been shown to vary over time and 
possibly in relation to other factors. 
 A mortality prevalence of 8.5% was reported for paediatric haematology-oncology BSI in 
Johannesburg for the period 1991 to 1995. Increased mortality was recorded in patients who 
were not commenced on antibiotic therapy shortly after obtaining specimens for blood 
culture. Gram-negative bacterial infections were also associated with increased mortality 
risk.15  
  A study in Cairo documented BSI associated mortality of 11.3% during the 2007-2008 
period.1 Viscoli et al in Italy reported a mortality prevalence of 11% within 30 days of the 
BSI.6 As this mortality estimate included deaths from the primary oncological disease process 
and treatment complications, BSI-associated mortality may have possibly been 
overestimated. More recently, Al-Mulla et al in Qatar reported a mortality prevalence 
estimate of only 2.2 % for the period 2004 to 2011.11 This low prevalence may reflect a more 
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aggressive approach to the investigation and management of BSI at this cancer treatment 
centre.  
 The reviewed publications employed a variety of measures for assessing morbidity. Some 
definitions of BSI-associated morbidity included the persistence of symptoms at day 7 of 
BSI, the need for ICU admission, the need for CVC removal for persistent BSI or 
hypotension during the BSI.1,5,22  
 The reported BSI-associated mortality prevalence also varied from cohort to cohort. The 
composition of cohorts also varied. For example, some cohorts only included paediatric 
haematology oncology patients, and others cancer patients with CVCs, or patients with a 
specific type of cancer such as AML. These differences may have influenced the variation of 
reported BSI associated mortality, which ranged from 2.2% in Qatar to 23% for VGS 
infection in Taiwan.22 
 
1.4.4 Variation of BSI pathogens in relation to cancer diagnosis. 
 Because of differences in risk factor profile and treatment regimens, it may be anticipated 
that the pathogens causing BSI may vary depending on the specific type of cancer. However, 
this literature review showed that only patients with AML experience an increased incidence 
of BSI caused by specific pathogens.  
 Johannsen et al in Norway demonstrated that for patients with AML, viridans group 
Streptococci and CONS were the predominant pathogens causing BSI, causing 43% and 9% 
of BSI, respectively.20 This infection pattern was attributed to mucositis, antibiotic 
prophylaxis and the presence of CVCs.22 Intensive chemotherapy regimens have been 
reported to increase the risk for VGS BSI, but this was not confirmed by Johannsen who 
showed that there was no statistically significant difference in the relative occurrence of VGS 
BSI in AML patients receiving high dose cytarabine and those receiving standard dose 
cytarabine (P=1.0). Creutzig et al demonstrated more infections during the consolidation 
phase of treatment with cytarabine than during the more intensive induction chemotherapy 
phase.30 This underlines the importance of the other factors that increase the occurrence of 
VGS BSI in AML patients. Higher incidence of VGS BSI in AML patients was confirmed in 
studies from Taiwan and Israel.13,22  
 
1.4.5 Factors influencing morbidity and mortality in cancer patients with BSI  
Specific factors are associated with increased morbidity and mortality in oncology patients 
with BSI. In an Egyptian study published in 2005, 30.2% of children with BSI experienced 
persistent fever for ≥ 7 days. Factors associated with this complication included being 
hospitalized, having intensive chemotherapy, polymicrobial infection, lower respiratory tract 
infection and persistent neutropaenia. Factors associated with death included being 
hospitalised, relapse disease, polymicrobial infection and lower respiratory tract infection.1 
Gram-negative BSI has been associated with a significant risk of complications, particularly 
septic shock.6,11 Furthermore, infection caused by multidrug resistant pathogens is a major 
contributor to mortality in oncology patients.11,31,32 
Although not as common as Gram-positive or Gram-negative infections, fungal BSI causes 
high morbidity and mortality.4 A Taiwanese study documented a mortality prevalence of 
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33.4% in children with candida CLABSI, significantly higher than in children with BSI 
caused by more common pathogens such as enterobacteriaceae (7.8%) or CONS (7%).  Due 
to difficulty of treating candida CLABSI, CVC removal is necessary in up to 66.7% of 
patients with this infection. Invasive mycoses particularly have a poor prognosis.33 
 Bloodstream infection-associated mortality is also high in children who have received a 
HSCT.6,34 
1.4.6 BSI-associated risk factors 
  Multiple factors have been demonstrated to increase risk for BSI in paediatric cancer. These 
risk factors include the presence of neutropaenia, indwelling CVCs, hospitalisation for cancer 
treatment, HSCT, surgical interventions and relapse of the cancer.   
Neutropaenia is a known risk factor for BSI due to the decreased functional capacity of the 
immune system.4,19,22 Castagnola in Italy showed that amongst leukaemia patients with a BSI, 
80% had neutropaenia. Not only does the presence of neutropaenia have an impact on the 
occurrence of BSI, but so does the duration of neutropaenia. Patients with prolonged 
neutropaenia have been shown to have increased risk of BSI.7,8 This increased risk of BSI in 
neutropaenia is more pronounced in patients with haematological cancers. In another study in 
Italy, amongst leukaemia patients 84% of BSI occurred in the presence of neutropaenia.6 In 
contrast, amongst patients with solid tumours, 47% of BSI occurred in the presence of 
neutropaenia. Patients with neutropaenia are susceptible to a specific array of pathogens 
causing BSI. In France, a study showed that neutropaenic patients with BSI had significant 
higher rates of oral streptococcal strains, Enterobacteriaceae and Pseudomonas species on 
blood culture. This risk is compounded by neutropaenic patients having increased risk of 
developing HAI.26 Patients with prolonged neutropaenia are also particularly at risk for fungal 
infections. For this reason antifungal prophylaxis is recommended in patients where 
neutropaenia is anticipated to last at least 7-10 days.35 
 In paediatric oncology patients, CVCs are important for the administration of antineoplastic 
therapy, blood components and nutrition, and recurrent blood sampling.29 However, CVCs 
increase the risk of BSI.28 The risk for BSI is also influenced by the type of CVC. Total 
external devices (TEDs) such as Hickman CVCs have been shown to pose a higher risk for 
BSI compared to totally implanted devices (TIDs) such as Port-A-Caths.  A prospective study 
in New Mexico reported that patients with TED CVCs have a 7-fold higher risk of 
developing BSI in comparison to those with TID CVCs.17 Similar findings were reported 
from Israel and Tennessee, USA although the relative difference was lower in those 
studies.23,24,28 The spectrum of pathogens causing BSI is also influenced by the type of CVC. 
In Johannesburg, patients with Hickman catheters were shown to preferentially develop 
Gram-negative sepsis. However, Hickman CVCs was the only type of CVC used in the study 
patients. In Israel, patients with different CVC types were shown to have a statistically 
significant difference in infection pattern in relation to the CVC type. Patients with Hickman 
lines predominantly had Gram-negative catheter-associated BSIs whilst patients with TID 
CVCs mainly had Gram-positive infections.23 A similar pattern was reported in another 
Israeli study.24Fungal BSI is also associated with indwelling CVCs particularly with TED 
CVCs.15,19  
  Oncology patients tend to require indwelling CVCs for lengthy periods of time whilst under 
treatment, including periods when neutropaenia is absent. During the maintenance phase of 
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chemotherapy when neutropaenia is usually absent CVCs remain a major risk factor for the 
development of BSI.19 Overall, the risk for the development of CVC-associated BSI was 
shown to be highest soon after CVC insertion possibly due to co-existing neutropaenia which 
develops after the commencement of chemotherapy.17 Another contributing factor could be 
sub-optimal management of indwelling CVC by the family during the initial period of 
chemotherapy. Although neutropaenia is a known risk factor for BSI, other risk factors 
should be considered. For example, in a prospective multicentre study completed in Italy 
there was a difference in the occurrence of CVC-associated BSI between patients with 
neutropaenia and without neutropaenia. Here the proportion of catheter-associated infections 
was 20% in neutropaenic patients in comparison to 55% in non-neutropaenic patients.6 This 
difference was statistically significant. This underlines the morbidity associated with CVCs, 
even in the absence of neutropaenia.  
 Patients receiving chemotherapy or other therapies for cancer require repeated 
hospitalisation. Hospitalisation per se is a risk factor for HAI. In a study in France 64% of 
BSIs were hospital-acquired.26 A study in Egypt showed that HAIs were significantly more 
frequent in neutropaenic patients than non-neutropaenic patients. Hospitalisation was shown 
to increase risk of catheter-associated BSI (CABSI) in Israel.22 However; an American study 
reported that the majority of CABSIs occurred in ambulatory patients.5 These contrasting 
findings may be related to different local management practices and differences in the length 
of hospitalisation in patients with CVCs on chemotherapy. The definition used for CABSI 
and CLABSI in the published literature was the same as the definition of CLABSI proposed 
by the Center for Disease Control and Prevention.36 
 Depending on the primary cancer diagnosis and the response to therapy, some patients may 
need HSCT. Haematopoietic stem cell transplantation increases the risk for BSI particularly 
in the pre-engraftment period.2 In Israel, patients were shown to have a 2-fold increased risk 
of developing a CABSI following HSCT.23 Similarly, in another study post-HSCT patients 
were shown to have a high incidence of BSI, even higher than in myeloid leukaemia.13 
However, in this study only 6 patients underwent HSCT, thus clear conclusions cannot be 
deduced. Increased risk of BSI post-HSCT has been shown not only to increase bacterial BSI 
but also invasive fungal infections.37 This increased risk for BSI following HSCT is higher 
post-allogeneic HSCT than with autologous stem cell transplant.34 
 The age at diagnosis of paediatric oncology patients varies widely and is influenced by the 
specific cancer diagnosis. Age may influence the risk for BSI. However, in studies completed 
in France and Israel, younger age was not shown to be associated with BSI.13,28 
 
1.4.7 Antibiotic susceptibility patterns  
 Patients with cancer may mount a sub-optimal immune response to infection. Hence it is 
important to optimise antibiotic choices including empiric antibiotic therapy for BSI, 
particularly in settings where resistance to commonly used antibiotics is frequent. For 
example, Egyptian studies have documented high frequencies of antibiotic resistance among 
pathogens causing BSI in children with oncological conditions.1,12   An Israeli study 
documented higher antibiotic resistance among Gram-negative pathogens, particularly 
Pseudomonas, Klebsiella and Acinetobacter isolates, although these pathogens were not 
associated with increased mortality.24 
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Resistance has also been documented among viridans group streptococci. A Norwegian study 
showed that 40% of viridans group streptococci causing BSI in cancer patients between 2004 
and 2011 were resistant to penicillin.20 Similarly in Taiwan 56% VGS isolates cultured from 
haematology-oncology patients between 1998 and 2004 were resistant to penicillin.22 Multi-
drug resistance is a particular concern. In Qatar a study of BSI in oncology patients on 
chemotherapy showed that 28.4% of bacterial isolates were multidrug resistant. Multi-drug 
resistant pathogens caused the BSI in 3 of 4 children who died as a consequence of their BSI 
.11 
 
1.5 Research gaps: 
This literature review showed that BSI is a frequent occurrence in paediatric oncology 
patients and an important cause of morbidity and mortality. Increased risk for BSI may be 
due to the cancer itself, chemotherapy, CVCs, hospitalisation and infections of multi-drug 
resistance.  
  However, from a South African and sub-Saharan African perspective, the following gaps in 
knowledge were identified in this literature review. 
1- Paucity in publications from South Africa and the rest of Africa. Only 1 article was 
from South Africa was identified, published approximately 20 years ago. 
2- The majority of the publications reviewed did not analyse the antibiotic susceptibility 
pattern of the pathogens causing BSI and there is no literature on the antibiotic 
susceptibility patterns of BSI in paediatric oncology in South Africa. 
3- Morbidity and mortality was not consistently described. When morbidity was 
described, there was a marked variation in how morbidity was defined. Common 
complications of BSI in oncology patients have not been adequately documented in 
African settings. 
4- A description of fungal BSI was not included in many studies. Most articles focussed 
exclusively on BSI caused by bacterial pathogens. 
5- Limited study of the relationship between the phase of chemotherapy or bone marrow 
status and BSI risk or outcome after BSI. 
6- Limited study of the relationship between non-chemotherapeutic interventions such as 
surgery and radiotherapy and the risk of BSI in paediatric oncology patients. 
7- Limited understanding of the impact of HIV infection on the risk and outcome of BSI. 
 
 The following study on the epidemiology of BSI at RCWMCH aims to bridge some of these 
knowledge gaps, by exploring the spectrum of bacterial and fungal pathogens causing BSI, 
the morbidity and mortality of BSI and the antibiotic susceptibility patterns of pathogens 
causing BSI in children with an underlying oncological condition, treated at a South African 
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2.1 Abstract 
 Background: Infections cause significant morbidity and mortality in children with cancer, 
which may be related to the cancer or treatment received. There is paucity of data on the 
epidemiology of bloodstream infection (BSI) in sub-Saharan Africa. To address this 
knowledge gap, this study was conducted at Red Cross War Memorial Children`s Hospital 
(RCWMCH) in Cape Town, South Africa. 
Methods: A retrospective cohort study was conducted at the haematology-oncology unit of 
RCWMCH. All positive blood cultures from RCWMCH oncology patients taken between 1 
January 2012 and 31 December 2014 were retrieved to identify patients who had BSI. 
Results: From 436 positive blood culture results, 150 BSI episodes were identified amongst 
89 patients; 49.1% of the culture isolates were Gram-positive bacteria, 41.6 were Gram-
negative bacteria and 9.3% were fungal. Coagulase Negative Staphylococcus and Viridans 
Group Streptococcus were the most common Gram-positive isolates, and Escherichia coli 
and Klebsiella species the commonest Gram-negative isolates. The majority of BSI episodes 
occurred in patients with haematological malignancies (74%), in the presence of severe 
neutropaenia (76.4%) and whilst on or following chemotherapy (88%). Complications 
occurred in 14% of the BSI episodes. Fungal infections had the highest prevalence of 
complications (21.4%). Three children died during BSI as a result of multidrug resistant 
isolates, giving a case-fatality rate of 2%.  
Conclusion: BSI in our patients are mainly caused by Gram-positive bacteria and associated 
with a low case-fatality rate. The results of this study are consistent with worldwide 
experience of BSI in paediatric oncology patients.  




Infections are a significant contributing factor to morbidity and mortality in paediatric 
oncology.1,2 Immunity may be compromised by cancer itself or therapeutic interventions. 
Patients with haematological malignancies and cancers with bone marrow infiltration are at 
increased risk of infection. Bone marrow suppression with neutropaenia and/or lymphopaenia 
may occur as a result of chemotherapy and radiotherapy rendering the innate and adaptive 
immune systems dysfunctional.3,4,5 Such patients easily develop opportunistic infection.6  
  With advances in cancer treatment, more intensive treatment regimens have been introduced 
leading to increased cure rates but also increased infection risk.  Hence the high rate of 
infection in patients with acute myeloid leukaemia (AML) where very myelosuppressive 
chemotherapy causes profound and prolonged neutropaenia.7  
 Cancer patients have increased exposure to pathogens because of indwelling vascular access 
devices (VAD) and frequent hospitalisation. This places them at risk for hospital-acquired 
infections (HAI) which carry high morbidity as they are frequently caused by multi-drug 
resistant (MDR) organisms.8 
 A number of studies have described the epidemiology of bloodstream infections (BSI) in 
paediatric oncology worldwide. There is variation in the common pathogens, BSI risk factors, 
extent of morbidity or mortality and antibiotic susceptibility patterns as a result of 
1,2,7environmental factors, local cancer treatment regimens or antibiotic selection pressure.   
 There is a marked paucity of data on BSI amongst paediatric oncology patients in low and 
middle income countries (LMIC). At the research site, BSI is an important contributor to 
hospitalisation.9 No studies have been done in children with cancer at this site, and only one 
such study has been completed in South Africa.2 Therefore, we investigated the epidemiology 
of BSI in paediatric oncology patients at Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, South Africa, including the spectrum of pathogens, their 
antimicrobial susceptibilities and clinical outcomes.  
  
2.3 Materials and methods 
2.3.1 Study design and setting 
 This retrospective cohort study was conducted in the 17-bed haematology-oncology unit at 
RCWMCH in children with cancer who developed culture-confirmed BSI between 1 January 
2012 and 31 December 2014. This oncology unit serves approximately 50% of the children 
less than 15 years of age with cancer in the Western Cape Province and selected referrals 
from the Eastern Cape Province, diagnosing and treating between 100 and 130 children 
annually.  
2.3.2 Study population 
Blood culture specimens are collected in neutropaenic patients if they have an axillary 
temperature >37.5° Celsius (C) on at least two occasions, or an axillary temperature > 38oC 
on one occasion and/or have clinical features suggestive of infection. In non-neutropaenic 
patients, blood culture specimens are collected if the axillary temperature is ≥38°C and/or 
there are clinical features suggestive of infection. Culture specimens are obtained aseptically. 
A second culture is obtained if the axillary temperature rises over 38oC on a second occasion, 
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and then the patients are only cultured again if the clinical condition deteriorates. For this 
study, culture specimens had been collected aseptically either by peripheral venepuncture or 
from central lines. In patients with suspected BSI and VADs in situ, blood cultures were not 
routinely obtained from both the VAD and a peripheral vein. During the study period, 
Piperacillin-tazobactam and Amikacin was the empiric antibiotic regimen for suspected BSI 
in children with neutropaenia, whilst empiric Ceftriaxone was prescribed in the absence of 
neutropaenia. Patients at RCWMCH oncology unit with haematological malignancies  
routinely receive Cotrimoxazole as antibiotic prophylaxis for the duration of their treatment. 
Patients who are expected to have neutropaenia for longer than 7 days are given Fluconazole 
prophylaxis. Quinolones are not used for prophylaxis.  
 
During the study period, 3050 blood culture specimens were collected and processed by the 
National Health Laboratory Services (NHLS) microbiology laboratory based at Groote 
Schuur Hospital; 436 of these blood cultures yielded positive results. Organisms were 
stratified into pathogens and contaminants. Coagulase-negative staphylococci (CONS), 
Staphylococcus epidemidis, Bacillus spp. Micrococcus spp. and Coryneform bacteria were 
regarded as contaminants and excluded from the analysis unless they were cultured on two or 
more independent blood culture specimens within a 48-hour period, in which case they were 
regarded as pathogens.10 This approach was used irrespective of whether blood culture 
specimens were obtained by peripheral venepuncture or a central line. Isolates of 
Enterococcus species and Viridans group streptococcus (VGS) were considered pathogenic 
when isolated whilst there was a fever at the time of blood culture.  
 16 positive blood cultures were excluded because they were obtained from children with 
non-oncological haematological diseases. A further 77 were excluded because they yielded 
contaminants. The remaining 343 positive blood culture results were attributed to 150 BSI 
episodes in 89 oncology patients. There were 173 different culture isolates causing these 150 
BSI episodes. Amongst these 89 children, 56 had one episode of BSI and the remaining 33 
children had 2 or more episodes during the study period. Recurrent BSI was defined as the 
isolation of the same or different organism on blood culture more than 14 days after the initial 
or previous BSI. 
  Haematological tumours, solid tumours and central nervous system (brain) tumours are the 
3 main types of paediatric cancer. Research has shown variation in the incidence of BSI in 
relation to tumour type, with haematological cancer having a higher incidence.1 Amongst 
haematological cancers, AML patients are at a higher risk for BSI.6 To investigate variation 
in the occurrence of BSI, the study population was stratified into the three main types, and the 
haematological malignancies further classified into AML, acute lymphoblastic leukaemia 
(ALL) and non-Hodgkin lymphoma (NHL) sub-types.  
2.3.3 Data Collection 
     Clinical data relating to each BSI were extracted from patient hospital records and 
transferred to a study-specific data collection sheet. The date of each BSI, age, gender, 
weight, HIV status, temperature at time of blood culture, cancer diagnosis, details of prior or 
current chemotherapy, surgery or radiotherapy, presence and type of VAD, absolute 
neutrophil count (ANC) were documented. Microbiological results were obtained from the 




2.3.4 Microbiological procedures 
     Microbiological testing of blood culture specimens was completed at the Groote Schuur 
Hospital NHLS microbiology laboratory using the BACTECTM 9240 automated blood culture 
system (Becton Dickinson, Sparks, Maryland). If growth of any pathogen was detected, 
standard biochemical, disk diffusion and gradient diffusion antibiotic susceptibility tests were 
used to evaluate gram-positive organisms. Gram-negative organisms were identified and 
antibiotic susceptibility tested after direct inoculation of the bacterial colonies into the 
automated Vitek2 system [bioMérieux, Inc., France] using Vitek2 ID-GNB and AST-N064 
cards. Where necessary, repeat testing was done on bacterial colonies subcultured onto agar 
plates, using either Vitek2, disk diffusion or gradient diffusion E-test (bioMérieux, Marcy 
l’Etoile, France) methods. Fungal isolates identified on gram stain were inoculated onto 
sabouraud dextrose agar. Identification and susceptibility testing of fungi were carried out 
with the VitekR 2 system using YST identification and AST-YS07 cards. Susceptibility 
results were interpreted according to the Clinical Laboratory Standards Institute (CLSI) 
criteria for 2012 – 2014.11 
The following definitions were used: 
Nutritional status: moderate and severe underweight were defined as weight-for-age z score 
(WAZ) between -2 and -3 standard deviations (SD) below the median World Health 
Organisation (WHO) growth reference standards, and a WAZ < -3 SD respectively.  
HIV infection: HIV infection was diagnosed in a child <18 months old using HIV PCR test 
and in a child > 18 months using serological tests as per guidelines from Schneider et al.12 
 Neutropaenia: The presence of an ANC of < 1500 x 109/ L was regarded as neutropaenia. 
An ANC of < 500 x 109/ L was classified as severe neutropaenia.13 Although we employed 
this definition, it may differ from the definition used in other published studies. 
 Polymicrobial BSI: BSI episode whereby 2 or more different isolates were grown from the 
same blood culture sample.
 Venous Access Device (VAD):  An indwelling venous catheter that was inserted into the 
central venous system with the catheter tip positioned within the superior/inferior vena cava 
or right atrium, including Hickman, Port-A-Cath and central venous pressure (CVP) 
catheters.14 
2.3.5 Data analysis 
   All data were entered anonymously into a dedicated Microsoft Access 2013 version 15.0 
database. All analyses were performed using STATA IC version 14.1 (College Station, 
Texas). Frequency tables were used to summarise the baseline characteristics at the time of 
BSI. Baseline characteristics at time of BSI are presented as proportions with percentages if 
categorical and compared across cancer groups using Fisher’s exact test. Continuous data 
normally distributed are summarized using mean and standard deviation (SD) and compared 
across groups using Analysis of Variance (ANOVA) test. Skewed continuous data are 
summarized as medians with inter-quartile range (IQR) and compared across groups using 
Kruskal–Wallis test. Statistical significance was considered at a two-sided α-level of 0.05 
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2.3.6 Ethical considerations 
   The study was completed in accordance with the Declaration of Helsinki and approved by 
the Human Research Ethics Committee, Faculty of Health Sciences, University of Cape 
Town, reference number: HREC 021/2015. Informed consent was not obtained from 
individual patients or caregivers because the data was collected retrospectively. Patient 
details were anonymised before data analysis.  
2.4 Results 
2.4.1 Prevalence of bloodstream infection 
   During the study period, 332 cancer patients were managed in the oncology unit. BSI was 
more common amongst children with AML than those with other tumours, 27/33 (81.8%) vs 
62/299 (20.8%), risk ratio 3.9, 95% confidence interval: 3.0 – 5.2. Of all children who 
experienced BSI episodes, those with AML experienced close to twice the BSI episodes per 
child compared to those with brain tumours (Table 1). 
 
2.4.2 Baseline patient characteristics 
  Table 2 summarises the patient characteristics at the time of BSI and disaggregates this 
information according to cancer type and haematological cancer sub-type. The mean age at 
the time of BSI was higher among patients with haematological malignancies compared to 
those with other cancers but this difference was not statistically significant. Overall, 23.3% 
(35/150) BSI episodes were associated with moderate or severe underweight-for-age, and of 
108 episodes in which HIV status was documented, two (1.9%) occurred in patients with HIV 
infection. Severe neutropaenia was significantly more frequent in BSI episodes in patients 
with AML. Prolonged neutropaenia for at least 7 days was present in 40.5% of BSI episodes 
and significantly more frequent in BSI episodes with ALL or AML compared to other 
tumours.   
 Most BSI episodes occurred during the induction and consolidation phases of chemotherapy 
for haematological malignancies, and during the continuous phase of solid tumour 
chemotherapy. For the timing of BSI in relation to chemotherapy, 88% (132/150) occured 
within 30 days of receiving chemotherapy. A VAD was in situ at the time in 68% (102/150) 
of the BSI episodes, and was more frequent in episodes associated with AML and NHL. 
Amongst patients with VAD, 44.7% (59/132) experienced at least one BSI compared to 15% 
(30/200) in patients without VAD, p<0.01. 
 
2.4.3 Spectrum of microorganisms 
The majority of the 150 BSI episodes had no identifiable clinical focus of infection (Table 2) 
Of these episodes, 129 (86%) were caused by a single bacterial or fungal isolate 
(monomicrobial infections) i.e. 61 were caused by gram positive bacteria, 54 by gram 
negative bacteria, and 14 by fungal species.  The remaining 21 (14%) BSI episodes were 
polymicrobial infections. Nineteen and two polymicrobial BSI were caused by 2 and 3 
pathogens, respectively. These polymicrobial infections occurred amongst 20 patients, with 1 
patient experiencing two polymicrobial BSI. 
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    The distribution of the 173 BSI-causing microorganisms is summarised in Table 3. Gram-
positive bacteria, Gram-negative bacteria and fungi were responsible for 49.1%, 41.6 % and 
9.3% of the isolates, respectively. CONS, VGS and enterococcus species were the most 
frequently isolated Gram-positive bacteria. Of 72 Gram-negative bacterial isolates, 51 
(70.8%) belonged to the enterobacteriaceae family. All fungal isolates were Candida species. 
VGS was the commonest isolate in AML patients with BSI whilst CONS was the commonest 
isolate in ALL and NHL patients with BSI. 
 Of the 121 BSI associated with neutropenia, 52 (43%), 44 (36.4%), and 10 (8.3%) were 
single-isolate Gram-positive bacterial, Gram-negative bacterial and fungal infections 
respectively, and the remaining 15 (12.4%) BSIs were polymicrobial infections. By contrast, 
of the 23 episodes without neutropaenia, 8 (34.8%), 6 (26.1%), and 3 (13%) were single-
isolate Gram-positive bacterial, Gram-negative bacterial, and fungal infections, respectively, 
and 6 (26.1%) were polymicrobial infections. The proportion of single-isolate Gram-positive 
bacterial infections was higher when neutropaenia was present, but this was not statistically 
significant, p=0.46. The proportion of CONS was similar in BSI episodes associated with 
neutropaenia compared to episodes not associated with neutropaenia [31/121 (25.6%) vs 6/23 
(26.1%), p=1.0]. Furthermore, while the proportion of VGS was higher in BSI episodes 
associated with neutropaenia, this difference was not statistically significant, [(20/121 
(16.5%) vs 1/23 (4.31%), p=0.2)].  
    For patients with a VAD compared to those without VAD, single-isolate Gram-negative 
bacterial infections were significantly less common [ 31/102 (30.4%) vs 23/48 (47.1%), p= 
0.04]. Single-isolate Gram-positive bacterial, polymicrobial and single-isolate fungal 
infections were more common but not significantly different in BSI episodes with a VAD  [ 
44/102 (43.14%) vs 17/48 (35.4%), p=0.48], [16/102 (15.7%) vs 5/48 (10.4%), p=0.46], 
[11/102 (10.8%) vs  3/48 (6.3%), p=0.55], respectively. CONS occurred in higher proportion 
amongst BSI episodes with a VAD compared to episodes without a VAD [30/102 (29.4%) vs 
7/48 (14.6%), p=0.07] whilst Escherichia coli occurred less frequently [7/102 (6.9%) vs 9/48 
(18.8) (p=0.04)] 
   The distribution of infection types in relation to the different VADs that was present at the 
time of BSI is summarised in Figure 1. Of 102 BSI episodes with a VAD in situ, 58 (56.9%), 
37 (36.2%) and 7 (6.9%) had Hickman, Port-A-Cath and CVP catheters, respectively. Single-
isolate Gram-positive bacterial infections predominated in the presence of Hickman and Port-
A-Cath VADs. During the study period, amongst all 332 oncology patients managed in the
haematology-oncology unit, 124 (37.4%) required VADs. Amongst these 124 patients, 65
(52.4%), 47 (37.9%) and 12 (9.7%) had Hickman, Port-A-Cath and CVP catheters,
respectively.
  During the study period, 25 oncology patients were being followed up by the oncology unit 
after haematopoietic stem cell transplantation (HSCT). Seven BSI episodes occurred in 7 of 
these patients. Of these 7 BSI, 42.9% (3/7) were caused by Gram-positive bacteria, 42.9% 
(3/7) were caused by Gram-negative bacteria and 14.2% (1/7) were polymicrobial in 
aetiology. Amongst the 143 BSI not preceded by HSCT Gram-positive bacteria, Gram-
negative bacteria, polymicrobial growth and fungi caused 40.6% (58/143), 35.7% (51/143), 
pg. 33 
 
14% (20/143) and 9.8% (14/143), respectively. There was no difference in the spectrum of 
pathogens causing BSI in relation to HSCT (p=1.0) 
   Radiotherapy preceded 8% (12/150) of the BSI episodes. The difference in causative 
microorganisms when comparing BSI episodes preceded by radiotherapy and those not 
preceded by radiotherapy was minimal.   
   
2.4.4 Antibiotic and antifungal susceptibilities of BSI isolates 
    Table 4 shows the antimicrobial susceptibility patterns of the bacterial and fungal isolates 
causing BSI.  Low carbapenem resistance was documented amongst the Gram-negative 
bacteria. All fungal isolates were susceptible to amphotericin B. The median time to effective 
antimicrobial therapy was 0 (IQR 0-1) days in the 138 isolates where this information was 
known. In 61.6% (85/138) of these isolates, the empiric antibiotic therapy initiated at the time 
of blood culture acquisition was effective. Amongst the 137 bacterial isolates obtained from 
BSI episodes with neutropenia, 46 were tested for Pipericillin-tazobactam and Amikacin 
susceptibility and 13/46 (28.3%) were resistant to the standard empiric Pipericillin-
tazobactam and Amikacin regimen. 
2.4.5 Outcome 
    At least one complication including death occurred in 14% (21/150) of all BSI episodes. 
The more frequent complications were septic shock in 8% (12/150), respiratory failure in 
2.7% (4/150), renal failure in 2% (3/150) and multi-organ failure in 1.3% (2/150).  Other 
complications included GIT infection, bleeding or perforation (4), abscesses (2), 
coagulopathy or thrombosis (2) and empyema or pneumothorax (2). Complications occurred 
in 21.4% (3/14), 20.4% (11/54), 9.5% (2/21) and 8.2% (5/61) of fungal, Gram-negative 
bacterial, polymicrobial and Gram-positive bacterial BSI episodes respectively, p=0.19. 
Treatment in the intensive care unit (ICU) was required in 7.3% (11/150) of BSI episodes. 
Bloodstream infection episodes caused by isolates which were sensitive to the empiric 
antibiotic regimens were associated with fewer complications than episodes caused by 
resistant isolates, 9/85 (10.6%) vs 7/53 (13.2%), p=0.79,and fewer deaths, 2/85 (2.4%) vs 
2/53 (3.8%), p=0.64. These differences were not statistically significant. 
 During the study, there were 3 deaths from BSI giving a case-fatality rate (CFR) of 2%. Two 
of the deaths occurred in children with BSI caused by extended spectrum beta-lactamase-
producing Klebsiella pneumoniae isolates. One of these two children developed the 
Klebsiella pneumoniae BSI day 53 post-HSCT. The third death occurred in a patient with a 
polymicrobial BSI caused by Vancomycin-resistant Enterococcus faecium and Streptococcus 
viridans. This patient also had mucormycosis which was diagnosed on histological tissue 
examination of small and large bowel specimens collected on laparotomy. All 3 patients died 
in ICU, and on transfer to ICU, 2 had multi-organ failure and 1 had respiratory failure. 
2.5 Discussion  
  Since the 1970s an increasing proportion of Gram-positive bacteria has been noted as the 
cause of BSI in paediatric oncology.3,4,6,15,16 Similarly, in the present study Gram-positive 
bacteria particularly CONS and VGS were the predominant causes of BSI. A previous 
hospital-wide study at RCWMCH showed that Gram-negative bacteria are the main causes of 
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BSI.9 The susceptibility to Gram-positive bacteria among oncology patients may relate to 
several factors including the high prevalence of neutropaenia, intensive chemotherapy 
regimens, mucosal barrier defects and prophylactic antimicrobial use during periods of 
immune vulnerability. Neutropaenia disables the immune system, increasing the risk of 
infection and alters the spectrum of organisms that cause infection.7,17 Intensive 
chemotherapy increases this risk by causing neutropaenia and defects in mucosal barriers 
such as mucosits.3,18 Defects in mucosal barriers of the gastrointestinal tract increase the risk 
for infection by bacteria that normally colonise the gastrointestinal tract.18,19 
   Patients with haematological cancers at RCWMCH, particularly AML and ALL, were 
shown to have higher BSI frequency. Previous studies have shown that AML patients have 
higher risk of BSI than other malignancies, and are particularly susceptible to infections with 
VGS as is also demonstrated at RCWMCH.7,20,21 At RCWMCH, VGS is considered a 
pathogen if  isolated from a single blood culture specimen in a febrile child suspected of 
having BSI. The prevalence of VGS BSI in AML was similar in the induction and 
consolidation chemotherapy phases in our study. Similar findings were reported in 
Denmark.18  
 In Johannesburg and Doha the majority of BSI occurred in the absence of neutropaenia.2,3 
Some studies have however showed that neutropenia is a significant risk factor for BSI.7,8,22,23 
In the present study, the majority of BSI (76.4%) occurred in the presence of severe 
neutropaenia.  
  The presence of a VAD is an important risk factor for BSI. Furthermore, CONS was a 
frequent cause of BSI in patients with a VAD, whereas Gram-negative infections 
predominated in those without a VAD.17,24,25 In the Johannesburg study, more Gram-negative 
bacterial infections were reported with Hickman catheters whilst Gram-positive infections 
were more common in totally implantable VAD.2 A study in Ohio demonstrated increased 
VAD associated BSI incidence in the inpatient setting in comparison to the ambulatory 
setting. In Ohio, different types of pathogens were identified as the cause of BSI in relation to 
different VAD type. The pathogen type also varied whether the patient was an inpatient or 
not.26 In the present study, Gram-positive infections were commoner in Hickman and Port-A-
Cath types of VAD. This difference may be due to local practices. The current study at 
RCWMCH did not look into whether the first signs and symptoms of the BSI in patients with 
a VAD developed as an inpatient or outpatient. At RCWMCH, Gram-negative infections 
occurred significantly less frequently in patients with a VAD. By contrast, CONS occurred 
more commonly in the presence of a VAD. This suggests that the presence or absence of a 
VAD has an effect on changing patterns of pathogens causing BSI in patients. 
  Chemotherapy is also a risk factor for BSI because of neutropaenia, prolonged or repeated 
hospitalisation and the presence of VAD.3,27 Patients with prolonged hospitalisation may be 
colonised by hospital based pathogens and about 25% of them develop BSI.28  A study in 
cancer patients in France reported that 66.2% of BSI episodes were nosocomial.29 At 
RCWMCH, 88% of BSI episodes occurred within 30 days of chemotherapy, especially 
during the induction phase of haematological malignancy chemotherapy (35.3%) and the 
continuation phase of solid tumour chemotherapy (29.3%). Young age is another risk factor 
for BSI.20 
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The antibiotic susceptibility results suggest that the combination of Piperacillin-tazobactam 
plus Amikacin is an effective empiric antibiotic option for the majority of Gram-positive and 
Gram-negative infections and may continue to be used in the haematology-oncology unit in 
children with febrile neutropaenia.  However, the antimicrobial susceptibility results on the 
Gram-positive isolates in our study were incomplete, and the available evidence in Table 4 
show that a high proportion of the Gram-positive isolates are susceptible to Vancomycin. 
Hence, Vancomycin should be considered for patients who do not show a satisfactory clinical 
response to empiric therapy. 
 The high proportion of Gram-negative isolates that were susceptible to the carbapenems is 
reassuring and reflects the tight regulation of their usage in the unit. No resistance among 
fungal isolates to amphotericin B is also reassuring, especially when required for empirical 
treatment of children with severe infections. 
  In the present study, complications were more frequent in fungal BSI than bacterial BSI. 
Although fungal infections are often lethal, they are less frequent than bacterial infections.7 
The CFR of 2% was low in comparison to other studies. A study conducted in Johannesburg 
before 2000 documented a CFR of 8.5%, whereas a recent study conducted in Qatar recorded 
a CFR of 2.2%.2,3 Furthermore, a study of infectious complications in children with AML and 
Down syndrome reported no deaths from bacterial or fungal infections.30 Low mortality at 
RCWMCH may reflect an aggressive approach to monitoring for BSI in oncology patients, 
lower resistance rates of microbial isolates and the short median time to initiating effective 
antimicrobial therapy of 0 days.   
Study strengths and limitations 
A strength of this study is that it is one of few sub-Saharan African studies to describe 
bloodstream infections in childhood cancer. Although the results of this study are not 
generalizable to other paediatric haematology-oncology services in sub-Saharan Africa, it 
provides an understanding of the spectrum of organisms causing BSI and the outcome of BSI 
in an African context. The results highlight low mortality as a result of effective management 
of both the patients and the existing antimicrobial resources. Due to the retrospective design, 
there are limitations in the completeness of the clinical and laboratory data, and antimicrobial 
susceptibilities were incompletely evaluated. Because of low numbers of children with HIV 
infection, it was not possible to explore the effect of HIV infection on the course and 
outcome of BSI in this study, Furthermore, few deaths meant that risk factors for mortality 
were not evaluated by univariate and multivariate analyses.  
2.6 Conclusion 
BSI in our paediatric haematology-oncology unit is mainly caused by Gram-positive bacteria, 
in keeping with worldwide experience. Patients with haematological cancer, particularly 
AML were demonstrated to have the higher risk of BSI. Low levels of carbapenem resistance 
among Gram-negative isolates are encouraging. A prospective study involving multiple 
paediatric oncology centres is required to address limitations identified in the present study 
and provide a more comprehensive understanding of BSI in children with cancer in South 
Africa and sub-Saharan Africa. 
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2.10 Tables, figures and legends 
Table 1: The distribution of cancer and the frequency of BSI amongst cancer patients in 












Total n (%) 
Number (%) of cancer 
patients 
33 (9.9%) 62 (18.7%) 39 (11.7%) 126 (38%) 72 (21.7%) 332 
Number (%) of cancer 
patients with BSI 
  27/33 
(81.8%) 










Number (%) of BSI 
episodes 
53 (35.3%) 41 (27.3%) 17 (11.3%) 35 (23.3%) 4 (2.7%) 150 
Number of BSI episodes per 
patient with BSI 
1.96 1.78 1.42 1.52 1.0 1.69 























Table 2: Characteristics at the time of BSI 
Parameter 
Number of BSI episodes 
AML 
N=53  



























Female 27 (50.9) 18 (43.9) 7 (41.2) 14 (40) 3 (75) 69 (46) 
Age category n (%)        
   < 5 years 30 (56.6) 23 (56.1) 8 (47.1) 26 (74.3) 3 (75) 90 (60)  
0.27 * 
 
   5-15 years 23 (43.4) 18 (43.9) 9 (52.9) 9 (25.7) 1 (25) 60 (40) 
Mean age ± SD in years  4.9 ± 3.6 5.1 ± 3.8 5.9 ± 3.5 4.1 ± 3.3 3.0 ± 1.9 4.8 ± 3.6 0.37 ǂ 
Median (IQR) weight–for-
















category, n (%) 
       
Moderate under-weight-















0.44 * Severe under-weight-for-













ANC at time of BSI, n (%)        
   <500 cells/µL 46 (88.5) 31 (79.4) 14 (82.3) 17 (51.5) 2 (66.7) 110 (76.4) 0.01 * 
  500 – 1500 cells/µL 2 (3.8) 4 (10.3) 0 (0) 5 (15.2) 0 (0) 11 (7.6) 
  > 1500 cells/µL 4 (7.7) 4 (10.3) 3 (17.7) 11 (33.3) 1 (33.3) 23 (16) 
Neutropaenia duration, n 
(%)  
       
    < 7days 23 (47.9) 15 (42.9) 12 (85.7) 20 (90.9) 2 (100) 72 (59.5)  
<0.01 *     ≥ 7days 25 (50.1) 20 (57.1) 2 (14.3) 2 (9.1) 0 (0) 49 (40.5) 
Isolate count per BSI        
Monomicrobial 48 (90.6) 35 (85.4) 12 (70.6) 30 (85.7) 4 (100) 129 (86)  
0.36 * Polymicrobial  5 ( 9.4) 6 (14.6) 5 (29.4) 5 (14.3) 0  (0)  21 (14) 
Bone marrow status        
    In remission 31 (58.5) 17 (41.5) 2 (11.8) 3 (8.6) 0 (0) 53 (35.3)  
<0.01 *     Not in remission 10 (18.9) 11 (26.8) 0 (0) 6 (17.1) 0 (0) 27 (18.0) 
    Not investigated 12 (22.6) 13 (31.7) 15 (88.2) 26 (88.3) 4 (100) 70 (46.7) 
Chemotherapy phase at 
time of BSI 
       
Induction 30 (56.6) 21 (51.2) 2 (11.8) 0 (0) 0 (0) 53 (35.3)  
Consolidation 19 (35.8) 8 (19.5) 0 (0) 0 (0) 0 (0) 27 (18)  
Intensification 0 (0) 4 (9.8) 0 (0) 0 (0) 0 (0) 4 (2.7)  
Maintenance 0 (0) 1 (2.4) 0 (0) 3 (8.6) 0 (0) 4 (2.7)  
Continuous 1 (1.9) 1 (2.4) 14 (82.3) 24 (68.6) 4 (100) 44 (29.3)  
No chemotherapy 3 (5.7) 6 (14.6) 1 (5.9) 8 (22.8) 0 (0) 18 (12)  
Clinical focus of infection        
   Yes 21 (39.6) 11 (26.8) 11 (64.7) 12 (34.3) 0 (0) 55 (36.7)  
0.04 *    No 32 (60.4) 30 (73.2) 6 (35.3) 23 (65.7) 4 (100) 95 (63.3) 
  Venous access device        
     Present 47 (88.7) 19 (46.3) 15 (88.2) 20 (57.1) 1 (25) 102 (68)  
<0.01 *      Absent 6 (11.3) 22 (53.7) 2 (11.9) 15 (42.9) 3 (75) 48 (32) 
Recorded temperature        
     >35.5-37.9 degrees    
      Celsius 
9 (20.5) 2 (12.5) 0 (0) 1 (9.1) 0 (0) 12 (16)  
0.87 * 
     >=38 degrees Celsius 35 (79.5) 14 (87.5) 3 (100) 10 (90.9) 1 (100) 63 (84) 
Surgical procedure within 
last 3 months 
       
   Yes 43 (81.1) 16 (39) 15 (88.2) 16 (45.7) 2 (50) 92 (61.3)  
<0.01 *    No 10 (18.9) 25 (61) 2 (11.8) 19 (54.3) 2 (50) 58 (38.7) 
HIV status        
Infected 0 (0) 0 (0) 2 (11.8) 0 (0) 0 (0) 2 (1.3)  
0.07 * Uninfected 38 (71.7) 27 (65.9) 14 (82.3) 24 (68.6) 3 (75) 106 (70.7) 
Not documented 15 (28.3) 14 (34.1) 1 (5.9) 11 (31.4) 1 (25) 42 (28) 
Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; NHL, non hodgkin 
lymphoma; VAD, venous access device 
Bone marrow status was determined from the last haematological examination of bone marrow aspirate and or trephine biopsy performed on 
the patient. 
* Fischer`s exact test; ǂ ANOVA test; ᴪ Kruskal-Wallis test 
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     Table 3: Distribution of blood culture isolates in relation to malignancies 
 
Pathogen AML n (%) 
 
N=59 
ALL n (%) 
 
N=47 





















   30 (50.8) 
 
   25 (53.2) 
 
  13 (59.1) 
 
   17 (41.5) 
 




   11 (18.6) 
 
   15 (31.9) 
 
    9 (40.9) 
 
     5 (12.2) 
 




    16 (27.1) 
 
     1  (2.1) 
 
    1 (4.5) 
 
     5 (12.2) 
 
23 13.3 
Enterococcus species  
      3 (5.1) 
 
      2 (4.3) 
 
    3 (13.6) 
 






      3 (6.4) 
  
     3 (7.3) 
 
6 3.5 
Staphylococcus aureus     
      4  (8.5) 
  
     1 (2.4) 
              
           5  2.9 
Bacillus species   
 
  
     2 (4.9) 
 
          2 1.2 




     24 (40.7) 
 
    15 (31.9) 
 
    8 (36.4) 
 
    21 (51.2) 
 
4 (100) 72            41.6 
Escherichia coli  
9 (15.3) 
 
      7 (14.9) 
 
    1 (4.5) 
 
       1 (2.4) 
 
1 (25) 19            11.0 
Klebsiella species  
       9 (15.3) 
 
       2 (4.3) 
 
     1 (4.5) 
 
       4 (2.3) 
 
      2 (50) 18             10.4 
Enterobacter species  
      
 
        1 (2.1) 
 
     1 (4.5) 
 
       5 (12.2) 
 
          7             4.0 
Serratia marcescens   




     2 (9.1) 
  
          3            1.7 
Salmonella species   
 
  
       2 (4.9) 
 
      1 (25)           3             1.7 
Proteus mirabilis   
 
 
     1 (4.5) 
  
         1            0.6 
Acinetobacter species  
        2 (3.4) 
 
         1 (2.1) 
 
     1 (4.5) 
 
       3 (7.3) 
 




        1 (1.7) 
 
         2 (4.3) 
 
     1 (4.5) 
 
       2 (4.9) 
  




        2 (3.4) 
 
         1 (2.1) 
  
       1 (2.4) 
 
          4             2.3 
Haemophilus 
influenzae 
    
       3 (7.3) 
 
3             1.7 
Moraxella species   
         1 (2.1) 
   
1             0.6 
        
Fungi  
 5 (8.5) 
 
         7 (15) 
 
     1 (4.5) 
 
       3 (7.3) 
 
0 16            9.3 
Candida parapsilosis  
        2 (3.4) 
 
         2 (4.3) 
 
     1 (4.5) 
  
          5              3 
Candida albicans  
        1 (1.7) 
 
         1 (2.1) 
  
       2 (4.9) 
 
         4             2.3 
Candida krusei  
        2 (3.4) 
 
         2 (4.3) 
   
         4             2.3 
Candida tropicalis    
         2 (4.3) 
  
       1 (2.4) 
 










Table 4: Antimicrobial susceptibility results 
Antibiotic Number of isolates tested Number (%) of isolates 
resistant 
I. Gram-positive bacteria (n= 85) 
Rifampicin 23 21 (91.3) 
TMP/SMX 38 32 (84.2) 
Cloxacillin 38 32 (84.2 
Ampicillin 74 61 (82.4) 
Ciprofloxacin 7   5 (71.4) 
Erythromycin 43 29 (67.4) 
Clindamycin 37 21 (56.8) 
Vancomycin 54   3 (5.6) 
Linezolid 27   1 (3.7) 
II. Gram-negative bacteria (n= 72) 
Ampicillin 42 34  (81) 
TMP/SMX 64 46 (71.9) 
Co-Amoxiclav 41  27 (65.9) 
Tobramycin   8   4  (50) 
Ceftriaxone 42 21 (50) 
Ceftazidime 55 26 (47.3) 
Cefepime 58 24 (41.4) 
Nalidixic acid 12   4  (33.3) 
Gentamicin 44 12 (27.3) 
Piperacillin - tazobactam 34   9 (26.5) 
Amikacin 58 14 (24.1) 
Ciprofloxacin 63  15 (23.8) 
Colistin 40    7 (17.5) 
Meropenem 56    3 (5.4) 
Imipenem 56    3 (5.4) 
Ertapenem 45    1 (2.2) 
Fungal isolates (n= 16) 
Fluconazole 16    5 (31.3) 
5-Fluorocytosine 14    3 (21.4) 
Amphotericin B 15    0   (0) 

































3.1 Data Collection Sheet 
Study Title: Epidemiology of Blood stream infections in Oncology patients at Red Cross 




Date of Blood culture 
Date of Birth        :
Age at time of blood culture 
Gender Male      Female 
Primary Oncological 
diagnosis 
Date of Diagnosis 
Staging of Oncological 
diagnosis 
Additional underlying 
diagnosis if any 
Weight (Kg ) Weight for Age (Z-score) 
Treatment: 
Chemotherapy       Yes     No  
If yes, phase of treatment : ( chemotherapy block ) 
Chemotherapeutic 
medications within the last 






































Date of  starting 




Date of last chemotherapy 
dose prior to blood culture 
 
 




Number days between last 
day of chemotherapy to 
blood culture 
 
Radiotherapy         
 
Yes No 



















Surgery in the last 3 
months 
Yes   No 
If Yes, date of surgical 
procedure 
Surgical procedure(s)  
Haematopoietic Stem Cell 
Transplantation     (HSCT ) Yes No 
If Yes, Day post HSCT 
Biological agents given?     Yes No 
If yes what agents and date Agent   1    Date 
Agent 2 Date 
Was the patient undergoing 
relapse of the malignancy? 
Yes No 
If yes, number of relapse 
Haematological Investigations at time or closest to blood culture: 
Full Blood Count (FBC ) at 
time of blood culture 
Date: 
White Cell Count 
















                                                            x109/L 
 




Date of last bone marrow 




From bone marrow findings 
was patient in remission? 
 
Metastasis of tumour to other organs or systems at time of infection?   
                                                                 Yes                                                      No 










Patient tested for HIV YES NO UNKNOW
N 
HIV Test Date Result 
Rapid   
HIV ELISA   
HIV DNA PCR   
CD4 completed YES NO UNKNOWN 
CD4 date  
CD4 absolute count  CD4 percentage  
Most recent Viral load at 
time of blood culture 
 Date  Log  
VAD 
Presence of Vascular 






If yes, type of VAD   
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(circle) Port-A-cath Hickman line 
Broviac line Other central line (specify 
) 
Date of insertion of VAD. 
Any abnormal symptoms 
or signs of from site of 
VAD 
Yes  No 
      If yes 
Symptom Sign 
Occurrence of fever 
Fever: Temperature at time of blood culture sample 
collection 
C 
Focus of infection 
Pneumonia Urinary tract infection 
Meningitis Soft tissue infection 
Septic arthritis Osteomyelitis 
Catheter related blood stream infection Other (specify ) 
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Blood culture 





growth (hours ) 
Site of blood sample 
collection 
Peripheral site VAD 
Antibiotic sensitivity to cultured organism 
Piptazobactam S I R N/S 
Amikacin S I R N/S 
Ceftriaxone/ 
Cefotaxime 
S I R N/S 
Ceftazidime S I R N/S 
Cefepime S I R N/S 
Ampicillin S I R N/S 
Cloxacillin S I R N/S 
Cotrimoxazole S I R N/S 
Co Amoxiclav S I R N/S 
Erythromycin S I R N/S 
Ciprofloxacin S I R N/S 
Clindamycin S I R N/S 
Imipenem S I R N/S 
Ertapenem S I R N/S 
Meropenem S I R N/S 
Vancomycin S I R N/S 






S I R N/S 




S I R N/S 
Nalidixic  acid 
 
S I R N/S 
Fluconazole S  I R N/S 
 
Amphotericin B S I R  N/S 
 
Foriconazole S I R N/S 
 
Other ( specify)  
 
S I R N/S 
 
 
Prior antibiotics.      
Any antibiotic commenced within 5 days 
prior to positive blood culture? 
 
 
Name        Date 
Commenced          




    
 
 
    
 
 
    
 
 
    
Antibiotic(s) commenced at time of blood culture sample collection (empiric 
antibiotics):      
Name        Date 
Commenced          
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Use of alternative line antibiotics/ antifungals 
Second line antibiotics / antifungals commenced?  Yes No 
If Yes 
Name Date 
Commenced         
Date stopped  Route          Duration 
Time to effective antibiotic therapy: 
(Duration between blood culture collection to commencement of 
antibiotics organism cultured is sensitive to) ( days ) 
Complications: 
Septic shock    Respiratory failure 
Coma    Disseminated Intravascular coagulation 
Renal failure    Liver failure 
Other ( specify ) 
Maximal level of care provided 
Need for ICU admission     
Oncology ward ( G1) care 
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Any limitation of care to patient ( Intervention level ), if Yes Specify 
Hospital outcome from infection 
   Discharged  Death 
Date of discharge / death 
If outcome death, cause of death: 
Post-mortem done after death? 
If yes, post-mortem findings 
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3.3 Instructions to Authors of the target journal 
The Pediatric Infectious Disease Journal (PIDJ) 
Online Submission and Review System 
SCOPE 
The Pediatric Infectious Disease Journal is a peer-
reviewed, multidisciplinary journal directed to 
physicians and other health care professionals who 
manage infectious diseases of childhood.  
Instructions for Authors (this page) 
Reprint Ordering
Permissions Requests
New Policy, effective for all articles submitted on or after April 15, 2017 
Articles that have received funding by major pharmaceutical companies, except Letters to the 
Editor, will be required to pay the following publication charges. The universal fee for all 
accepted manuscripts with major pharma funding is: $2000.00 US, plus an additional per-
page fee with 2 options: 1) $50 per page for print and online publication; or 2) $25 per page 
for online only publication. Once published, these articles will be available online by free 
access.  
Ethical/Legal Considerations 
A submitted manuscript must be an original contribution not previously published (except as 
an abstract or preliminary report), must not be under consideration for publication elsewhere, 
and, if accepted, must not be published elsewhere in similar form, in any language, without 
the consent of Wolters Kluwer Health, Inc. Each person listed as an author is expected to 
have participated in the study to a significant extent. Although the editors and referees make 
every effort to ensure the validity of published manuscripts, the final responsibility rests with 
the authors, not with the journal, its editors, or the publisher. All manuscripts must be 
submitted on-line through the journal's web site at http://pidj.edmgr.com/. See submission 
instructions under "Online manuscript submission."  
Patient anonymity and informed consent: It is the author's responsibility to ensure that a 
patient's anonymity be carefully protected and to verify that any experimental investigation 
with human subjects reported in the manuscript was performed with informed consent and 
following all the guidelines for experimental investigation with human subjects required by 
the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes 
or, if the eye area is the focus of the illustration, the patient's nose and mouth, and they should 
remove patients' names from figures unless written consent obtained from the patients is 
submitted with the manuscript.  
Copyright: The corresponding author will complete the copyright questions within the 
submission steps, and provide each co-authors email address. The co-authors are emailed a 
hyperlink via which they will verify their co-authorship and complete the Copyright Transfer 
and Disclosure Form within EM. The co-authors are not required to register for an account in 
EM and no new accounts are created for them, rather, they are completing a form that is tied 
to the submission record. 
Conflicts of interest: Authors must state all possible conflicts of interest in the manuscript, 
including financial, consultant, institutional and other relationships that might lead to bias or 
a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as 
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none declared. All sources of funding should be acknowledged in the manuscript. All 
relevant conflicts of interest and sources of funding should be included on the title page of the 
manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:  
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is 
currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for 
Organization X – the CME organizers for Company A. For the remaining authors none were 
declared.  
In addition, each author must complete and submit the journal's copyright transfer agreement, 
which includes a section on the disclosure of potential conflicts of interest based on the 
recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" 
(www.icmje.org/update.html).  
A copy of the form is made available to the submitting author within the Editorial Manager 
submission process. Co-authors will automatically receive an Email with instructions on 
completing the form upon submission.  
Compliance with NIH and Other Research Funding Agency Accessibility Requirements 
A number of research funding agencies now require or request authors to submit the post-
print (the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, Wolters 
Kluwer will identify to the National Library of Medicine (NLM) articles that require deposit 
and will transmit the post-print of an article based on research funded in whole or in part by 
the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other 
funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides 
the mechanism. 
Permissions: Authors must submit written permission from the copyright owner (usually the 
publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted 
form elsewhere, along with complete details about the source. Any permissions fees that 
might be required by the copyright owner are the responsibility of the authors requesting use 
of the borrowed material, not the responsibility of Wolters Kluwer.  
PREPARATION OF MANUSCRIPT 
Manuscripts that do not adhere to the following instructions are returned to the corresponding 
author for technical revision before undergoing peer review. Also, to streamline the review 
process, on reviewing newly submitted manuscripts, we will identify those that do not meet 
the mission of the journal, provide no new information or insights into management of 
infectious diseases or are of more local importance and better suited for a regional journal 
and return them immediately to the authors to allow them to submit their work elsewhere in a 
timely fashion. Case series take preference over single case reports.  
New Article Types 
Research Reports This section comprises manuscripts on all aspects of the molecular 
pathogenesis and immunologic mechanisms of bacterial, viral, fungal and other infections in 
infants, children and adolescents. The emphasis will be on manuscripts that present data that 
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are clinically applicable and provide a more thorough understanding of the pathophysiologic 
basis of infections in children and that could impact eventual treatment and prevention. The 
manuscripts can be formatted as original studies or brief reports and will be peer reviewed.  
HIV Reports The section comprises of high-quality, high-impact original articles and brief 
reports of epidemiologic, clinical, translational and implementation science studies pertaining 
to the prevention, treatment and outcomes of HIV infection in infants, children, and 
adolescents. 
New Policy, effective for all articles submitted on or after April 15, 2017 
Articles that have received funding by major pharmaceutical companies, except Letters to the 
Editor, will be required to pay the following publication charges. The universal fee for all 
accepted manuscripts with major pharma funding is: $2000.00 US, plus an additional per-
page fee with 2 options: 1) $50 per page for print and online publication; or 2) $25 per page 
for online only publication. Once published, these articles will be available online by free 
access. 
 
Vaccine Reports Articles that present data from Vaccine Phase II-IV studies will appear in 
this section. These manuscripts receive the same peer review as articles submitted as Original 
Studies. The universal free access fee for all accepted manuscripts in this category is: 
$2000.00 US, plus an additional per-page fee with 2 options: 1) $50 per page for print and 
online publication; or 2) $25 per page for online only publication. All articles in this series 
will be available online by free access. For manuscripts in this category, authors should refer 
to the “Guidelines for collection, analysis and presentation of vaccine safety data in pre- and 
post-licensure clinical studies” published in Vaccine (2009, vol. 27; pp 2282-8) and use case 
definitions as developed by The Brighton Collaboration (www.brightoncollaboration.org) 
whenever possible.  
ESPID Reviews and Reports (or purple pages) This section comprises invited concise 
reviews on all aspects of infections in infants, children and adolescents including bacterial, 
viral, fungal and parasitic infections. Reviews on prevention, diagnosis, therapeutic 
interventions and drugs as well as on teaching and conferences in pediatric infectious 
diseases are the focus of this section and will concentrate on novel findings, development and 
controversial issues.  
Manuscript Submission  
Online manuscript submission: All manuscripts must be submitted on-line through the new 
web site at http://pidj.edmgr.com/. First-time users: Please click the Register button from the 
menu above and enter the requested information. On successful registration, you will be sent 
an E-mail indicating your user name and password. Print a copy of this information for future 
reference. Note: If you have received an E-mail from us with an assigned user ID and 
password, or if you are a repeat user, do not register again. Just log in. Once you have an 
assigned ID and password, you do not have to re-register, even if your status changes (that is, 
author, reviewer, or editor). If you experience any problems, please contact Amy Newman, 
Journal Manager, at PIDJournal@outlook.com, Ph 830-865-1249, Fax 214-710-2175.  
Authors: Please click the log-in- button from the menu at the top of the page and on the next 
screen log into the system as an Author. Submit your manuscript according to the author 
instructions. You will be able to track the progress of your manuscript through the system. If 
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you experience any problems, please contact Amy Newman, Journal Manager, at 
PIDJournal@outlook.com, Ph 830-865-1249, Fax 214-710-2175. Requests for help and other 
questions will be addressed in the order received. To submit a completed manuscript, the 
following documents are required: Cover Letter, Title Page, Abstract, and Manuscript. Tables 
and figures are optional. Each portion of the manuscript must be submitted as separate 
documents (i.e. cover letter, title page, abstract, manuscript, tables and figures all saved as 
separate files). The text documents, cover letter, title page, abstract and manuscript are to be 
uploaded as Microsoft Word documents. Tables are to be created in Microsoft Word also. 
Excel tables will not load properly. All figures should be TIFF, EPS or PowerPoint files.  
General format: Submit manuscripts in English. Double space all copy, including legends, 
footnotes, tables, and references. Use a common font such as Arial or Times Roman in size 
12. Enumerate all pages of the manuscript, beginning with the Title Page as page 1, and
follow in sequence to the abstract, manuscript and all other attachments. If you are unfamiliar
with numbering, you can search HELP while in Microsoft Word, and it will show in detail
how to number all pages.
Title page: Title page must be submitted as a separate file. Include on the title page: (a) 
complete manuscript title; (b) authors' full names, highest academic degrees, and affiliations; 
(c) name and address for correspondence, including Fax number, telephone number, and E-
mail address; (d) all sources of support, including pharmaceutical and industry support, that
require acknowledgment; (e) list three to five key words for indexing; (f) an abbreviated title
of 55 characters or less used for the cover of the journal; and (g) a running head title of 44
characters or less including spaces used for page headings on the pages in which your article
is published.
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard 
Hughes Medical Institute (HHMI); and other(s).  
Structured abstract for Original Studies and Supplement Articles: Abstracts must be 
submitted as a separate file. Limit the abstract to 250 words. Do not cite references in the 
abstract. Limit the use of abbreviations and acronyms. Use the following subheads: 
Background, Methods, Results, and Conclusions (others may be added as needed).  
Unstructured abstract for Instructive Cases and Brief Reports: Abstract must be submitted 
as a separate file. Limit the abstract to 60 words. It must be factual and comprehensive. Limit 
the use of abbreviations and acronyms, and avoid general statements (e.g. "the significance of 
the results is discussed").  
Brief Reports: Papers for this section should be no longer than 5-6 double-spaced typed 
manuscript pages (fewer than 1500 words), 10 references and 1 figure or table. Word count 
does not include Title Page or Unstructured Abstract.  
Letters to the Editors: Letters to the Editors should pertain to articles published within the 
Pediatric Infectious Disease Journal or highlight important new clinical or laboratory insights. 
Text should contain 500 words or fewer and less than 5 references.  
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ESPID Reviews and Reports: ERR reviews should contain a maximum of 2000 words 
(including references) and include up to 10 references and 1 table or figure. There is no 
abstract. A maximum of four authors is allowed.  
Original Studies: Papers for this section do not have a word, reference, table or figure limit.  
Text: Organize the manuscript into four main headings, Introduction, Materials and Methods, 
Results, and Discussion. If a brand name is cited, supply the manufacturer's name and address 
(city and state/country).  
Abbreviations: For a list of standard abbreviations, consult the American Medical Association 
Manual of Style, 9th edition, or other standard sources. Write out the full term for each 
abbreviation at its first use unless it is a standard unit of measure. Abbreviations are allowed 
only if used three times or more in text.  
References: The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance, including those references cited in tables and figure legends at the 
chronological citation of the tables and figures in text. Cite unpublished data, such as papers 
submitted but not yet accepted for publication or personal communications, in parentheses in 
the text. If there are more than three authors, name only the first three authors and then use et 
al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal names, 
or access the list at http://www.nlm.nih.gov/tsd/ serials/lji.html. Sample references are 
given below.  
Journal article 
1. Trujillo M, Correa N, Olsen K, et al. Cefprozil concentrations in middle ear fluid. Pediatr 
Infect Dis J. 2000;19:268—270.  
Book chapter  
2. Grose C. Bacterial myositis and pyomyositis. In: Feigin RD, Cherry JD, eds. Textbook of 
Pediatric Infectious Diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 
1998:704—708.  
Entire book  
3. Nelson JD, Bradley JS. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 14th ed. 
Philadelphia: Lippincott Williams & Wilkins; 2000.  
Proceedings  
4. Harrigan PR, Dong W, Weber AE, et al. Highly mutated RT and protease [Abstract I-115]. 
In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 
CA, September 24 to 27, 1998. Washington, DC: American Society for Microbiology; 1998.  
 
Online journals  
5. Friedman SA. Preeclampsia. Obstet Gynecol. [serial online]. January 1988;71:22–37.  
World Wide Web  
6. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available 
at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997.  
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Figures: 
A) Creating Digital Artwork
1. Learn about the publication requirements for Digital Artwork:
http://links.lww.com/ES/A42
2. Create, Scan and Save your artwork and compare your final figure to the Digital
Artwork Guideline Checklist (below).
3. Upload each figure to Editorial Manager in conjunction with your manuscript text and
tables.
B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:
 Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High
resolution PDF files are also acceptable.
 Crop out any white or black space surrounding the image.
 Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution
of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT,
XLS) file.
 Photographs, radiographs and other halftone images must be saved at a resolution of
at least 300 dpi.
 Photographs and radiographs with text must be saved as postscript or at a resolution
of at least 600 dpi.
 Each figure must be saved and submitted as a separate file. Figures should not be
embedded in the manuscript text file.
Remember: 
 Cite figures consecutively in your manuscript.
 Number figures in the figure legend in the order in which they are discussed.
 Upload figures consecutively to the Editorial Manager web site and enter figure
numbers consecutively in the Description field when uploading the files.
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Figure legends: Include legends for all figures. They should be brief and specific, and they 
should appear on a separate manuscript page after the references. Legends should be part of 
the manuscript file on the disk. Use scale markers in the image for electron micrographs, and 
indicate the type of stain used.  
Color figures: The journal accepts for publication color figures that enhance an article. 
Authors who submit color figures will be given the option to pay the cost to publish the 
figures in color in print. If the authors decline to pay the color cost, color figures will be 
published in black-and-white in print and in color in the electronic version at no charge. 
There is no charge for publication of color figures as Supplemental Digital Content or in 
online only articles.  
Supplemental Digital Content  
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to 
Wolters Kluwer journals that enhance their article's text to be considered for online posting. 
SDC may include standard media such as text documents, graphs, audio, video, etc. On the 
Attach Files page of the submission process, please select Supplemental Audio, Video, or 
Data for your uploaded file as the Submission Item. All SDC files should be uploaded as the 
author would like them presented in the final article (ie, Figure legends should be appear on 
the same page as the Figure image). If an article with SDC is accepted, our production staff 
will create a URL linking to the SDC file. The URL will be placed where indicated by your 
in-text citations within the article. Please ensure these are in order and accurate. SDC files are 
not copyedited by Wolters Kluwer staff, they will be presented digitally as submitted. For 
SDC documents, any labels or legends should be included in the SDC file when submitted. 
For a list of all available file types and detailed instructions, please visit 
http://links.lww.com/A142.  
SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list 
number, and a description of the supplemental content if desired.  
Example:  
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive 
(see Table, Supplemental Digital Content 2).  
List of Supplemental Digital Content 
A list of SDC must be submitted at the end of the manuscript file. Include the SDC number 
and file type of the SDC. This text will be removed by our production staff and not be 
published. This is requested to ensure URLs are created for all SDC files for each article. 
Example: 
Supplemental Digital Content 1. Video 
Supplemental Digital Content 2. Table 
Supplemental Digital Content 3. Figure 
Supplemental Digital Content 4. Table 
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 
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10 MBs, authors should first query the journal office for approval. The preferred file type is 
Adobe PDF when possible (as opposed to image files, PowerPoint, or Word documents). For 
a list of all available file types and detailed instructions, please visit 
http://links.lww.com/A142. Please note: SDC files are not copyedited by Wolters Kluwer 
staff, they will be presented digitally as submitted.  
Tables: Create tables using the table creating and editing feature of your word processing 
software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. 
Provide a separate document for each table. Cite tables consecutively in the text, and number 
them in that order. Key each on a separate sheet, and include the table title, appropriate 
column heads, and explanatory legends (including definitions of any abbreviation not already 
defined in the text). Do not embed tables within the body of the manuscript. They should be 
self-explanatory and should supplement, rather than duplicate, the material in the text. In each 
table, the genus of each genus-species must be written out at its first appearance.  
Style: Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate 
Dictionary (10th edition) should be used as standard references. Refer to drugs and 
therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. 
Use code numbers only when a generic name is not yet available. Capitalize the trade names 
of drugs and place them in parentheses after the generic names. To comply with trademark 
law, include the name and location (city and state/country) of the manufacturer of any drug, 
supply, or equipment mentioned in the manuscript. Use the metric system to express units of 
measure and degrees Celsius or degrees Fahrenheit consistently throughout the manuscript to 
express temperatures, and use SI units rather than conventional units. Abbreviate "liter" in 
such forms as "3 units/L" and "5 mL"; write out when used alone (10 liters; 0.5-liter gavage). 
See also Day RA, ed. How to Write and Publish a Scientific Paper. 5th ed. Phoenix, AZ: The 
Oryx Press, 1998.  
Financial disclosure: In the cover letter, indicate all affiliations with or financial 
involvement in any organization or entity with a direct financial interest in the subject matter 
or materials of the research discussed in the manuscript (e.g. employment, consultancies, 
stock ownership). All such information will be held in confidence during the review process. 
Should the manuscript be accepted, the Chief Editors will discuss with the author the extent 
of disclosure appropriate for publication.  
AFTER ACCEPTANCE  
Open Access  
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. Authors may take advantage of the open access option at the point of acceptance 
to ensure that this choice has no influence on the peer review and acceptance process. These 
articles are subject to the journal's standard peer-review process and will be accepted or 
rejected based on their own merit.  
The article processing charge (APC) is charged on acceptance of the article and should be 
paid within 30 days by the author, funding agency or institution. Payment must be processed 
for the article to be published open access. For a list of journals and pricing please visit our 
Wolters Kluwer Open Health Journals page.  
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Authors retain copyright 
Authors retain their copyright for all articles they opt to publish open access. Authors grant 
Wolters Kluwer an exclusive license to publish the article and the article is made available 
under the terms of a Creative Commons user license. Please visit our Open Access 
Publication Process page for more information.  
Creative Commons license 
Open access articles are freely available to read, download and share from the time of 
publication under the terms of the Creative Commons License Attribution-NonCommerical 
No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any 
commercial purposes nor does it cover the reuse or modification of individual elements of the 
work (such as figures, tables, etc.) in the creation of derivative works without specific 
permission.  
Compliance with funder mandated open access policies 
An author whose work is funded by an organization that mandates the use of the Creative 
Commons Attribution (CC BY) license is able to meet that requirement through the available 
open access license for approved funders. Information about the approved funders can be 
found here: http://www.wkopenhealth.com/inst-fund.php  
FAQ for open access 
http://www.wkopenhealth.com/openaccessfaq.php 
Page proofs and corrections: Corresponding authors receive electronic page proofs to check 
the copyedited and typeset article before publication. Portable document format (PDF) files 
of the proofs are provided to the authors via Editorial Manager. An e-mail notification is sent 
to the authors when the proofs are available and require review. Complete instructions are 
provided with the e-mail.  
It is the author's responsibility to ensure that there are no errors in the proofs. Changes that 
have been made to conform to journal style stand if they do not alter the authors' meaning. 
Only the most critical changes to the accuracy of the content are made. Changes that are 
stylistic or are a reworking of previously accepted material are disallowed. The publisher 
reserves the right to deny any changes that do not affect the accuracy of the content. Authors 
may be charged for alterations to the proofs beyond those required to correct errors or to 
answer queries. Proofs must be checked carefully and returned within 24 to 48 hours of 
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